Market revenue in 2023 | USD 1,713.0 million |
Market revenue in 2030 | USD 2,345.3 million |
Growth rate | 4.6% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Home Care |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Home Care, Research & Manufacturing |
Key market players worldwide | Thermo Fisher Scientific Inc, Qiagen NV, Illumina Inc, Roche Holding AG ADR, BD, Agilent Technologies Inc, Myriad Genetics Inc, Koninklijke Philips NV, Abbott Laboratories, Hitachi Ltd, Danaher Corp, Prestige Medical |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pancreatic cancer diagnostic market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 64.27% in 2023. Horizon Databook has segmented the North America pancreatic cancer diagnostic market based on hospitals, outpatient facilities, home care, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
North America dominated the global pancreatic cancer diagnostics market in 2023 due to the advanced healthcare infrastructure and high healthcare expenditure, which is facilitating the widespread adoption of diagnostic technologies. Moreover, leading research institutions and biotechnology firms are focused on innovative diagnostic methods.
These factors are expected to propel the North America pancreatic cancer diagnostic market over the forecast period. In February 2024, Freedom, a biotechnology company focused on developing blood tests for early cancer detection, secured USD 254 million in funding from new and existing investors.
This funding would help Freedom advance its single-cancer and tailored Multicancer Early Detection (MCED) test pipeline, leveraging its multiomics platform. The financing was led by Roche, with participation from existing and new investors.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America pancreatic cancer diagnostic market , including forecasts for subscribers. This continent databook contains high-level insights into North America pancreatic cancer diagnostic market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account